LncRNA TSLC1-AS1 is a novel tumor suppressor in glioma

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 6, 2014, Pages 3065-3072

  Qin, Xiaoyong ^a,b   Yao, Jie ^a,c   Geng, Peiliang ^a   Fu, Xiangping ^a   Xue, Jinghui ^a   Zhang, Zhiwen ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 253 Hospital of PLA   (China)

^c PLA 161 Hospital   (China)

Author keywords

Glioma; Long non coding RNAs; Tumor suppressor

Indexed keywords

CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; IMMUNOGLOBULIN; LONG UNTRANSLATED RNA; SMALL INTERFERING RNA; TRANSCRIPTOME;

BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GLIOMA; HUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL ADHESION MOLECULES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; IMMUNOGLOBULINS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; RNA, SMALL INTERFERING; TRANSCRIPTOME; TRANSFECTION;

EID: 84904313151     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classifcation of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH and Louis DN. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333.
3. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-227.
4. Huarte M and Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 2010; 19: 152-161.
5. Spizzo R, Almeida MI, Colombatti A and Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene 2012; 31: 4577-4587.
6. Tsai MC, Spitale RC and Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011; 71: 3-7.
7. Nowacki S, Skowron M, Oberthuer A, Fagin A, Voth H, Brors B, Westermann F, Eggert A, Hero B, Berthold F, Fischer M. Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma. Oncogene 2008; 27: 3329-3338.
8. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F. Differential expression of neuronal genes defines subtypes of disseminatedneuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006; 12: 5118-5128.
9. Watabe K, Ito A, Koma YI and Kitamura Y. IGSF4: a new intercellular adhesion molecule that is called by three names, TSLC1, SgIGSF and SynCAM, by virtue of its diverse function. Histol Histopathol 2003; 18: 1321-1329.
10. Houshmandi SS, Surace EI, Zhang HB, Fuller GN, Gutmann DH. Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor. Neurology 2006; 67: 1863-1866.
11. Murakami Y. Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 2005; 96: 543-552.
12. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH, Murakami Y. TSLC1 is a tumor suppressor gene in human non-small cell lung cancer. Nat Genet 2001; 27: 427-430.
13. Lung HL, Cheung AK, Xie D, Cheng Y, Kwong FM, Murakami Y, Guan XY, Sham JS, Chua D, Protopopov AI, Zabarovsky ER, Tsao SW, Stanbridge EJ, Lung ML. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 2006; 66: 9385-9392.
14. Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, Zöchbauer-Müller S. Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007; 103: 283-291.
15. Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, Murakami Y, Imamura M. Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003; 63: 6320-6326.
16. Honda T, Tamura G, Waki T, Jin Z, Sato K, Motoyama T, Kawata S, Kimura W, Nishizuka S, Murakami Y. Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res 2002; 93: 857-860.
17. Williams YN, Masuda M, Sakurai-Yageta M, Maruyama T, Shibuya M, Murakami Y. Cell adhesion and prostate tumorsuppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4. Oncogene 2006; 25: 1446-1453.
18. Jansen M, Fukushima N, Rosty C, Walter K, Altink R, Heek TV, Hruban R, Offerhaus JG, Goggins M. Aberrant methylation of the 5-CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs. Cancer Biol Ther 2002; 1: 293-296.
19. Chen K, Wang G, Peng L, Liu S, Fu X, Zhou Y, Yu H, Li A, Li J, Zhang S, Bai Y, Zhang Y. CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease. Int J Cancer 2011; 128: 266-273.
20. Yang YX, Yang AH, Yang ZJ, Wang ZR and Xia XH. Involvement of tumor suppressor in lung cancer 1 gene expression in cervical carcinogenesis. Int J Gynecol Cancer 2006; 16: 1868-1872.
21. You Y, Ma L, You M, Li X, Wang S, Li H, Wu D, Yang H, Li ZY. TSLC1 gene silencing in cutaneous melanoma. Melanoma Res 2010; 20: 179-183.
22. Wahlestedt C. Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today 2006; 11: 503-508.
23. Faghihi MA and Wahlestedt C. Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol 2009; 1: 637-643.
24. Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, Diber A, Biton S, Tamir Y, Khosravi R, Nemzer S, Pinner E, Walach S, Bernstein J, Savitsky K, Rotman G. Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol 2003; 21: 379-386.
25. Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999; 91: 143-151.
26. Ando K, Ohira M, Ozaki T, Nakagawa A, Akazawa K, Suenaga Y, Nakamura Y, Koda T, Kamijo T, Murakami Y, Nakagawara A. Expression of TSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation. Int J Cancer 2008; 123: 2087-2094.
27. Deimling AV, Korshunov A and Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011; 21: 74-87.
28. Weber GL, Parat MO, Binder ZA, Gallia GL and Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2: 833-849.
29. Dasgupta B, Wen L, Perry A and David H. Gutmann1.glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 2005; 65: 236-245.
30. Chen LC, Han L, Zhang KL, Shi ZD, Zhang JX and Zhang AL. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling. Neuro Oncol 2012; 14: 1026-1036.